机构：[1]Department of Orthopedics, Huzhou Cent Hospital, Affiliated Cent Hospital HuZhou University, Huzhou, China[2]Department of Neurosurgery, The First Affiliated Hospital of Kunming Medical University, Kuming, China外科科室神经外科神经外一科（神经外科）昆明医科大学附属第一医院[3]Department of Neurosurgery, Huzhou Cent Hospital, Affiliated Cent Hospital HuZhou University, Huzhou, China
The incidence of gliomas is increasing. Although great progress in glioma treatment has been made, the clinical outcome remains unsatisfactory. Chemokine (C-C motif) ligand 2 (CCL2) plays a key role in different types of cancers, including glioma. However, the function of CCL2 in glioma chemoresistance is not fully understood. In the current study, CCL2 was significantly upregulated in glioma. More importantly, CCL2 and CCR2 were significantly upregulated in temozolomide (TMZ)-resistant glioma. TMZ-resistant malignant glioblastoma cells (U251/TMZ) had higher expressions of CCL2 and CCR2 and a higher level of glycolysis as compared to its parental cell line U251. Silencing of CCL2 in U251/TMZ cells inhibited glycolysis. Overexpression of CCL2 reduced TMZ-induced apoptosis through activation of the AKT pathway and promotion of glycolysis. Moreover, overexpression of CCL2 significantly reduced the antitumor effect of TMZ in vivo. In conclusion, CCL2 overexpression reduced the antitumor effect of TMZ by enhancing glycolysis through activation of AKT signaling. The findings highlighted the importance of CCL2/CCR2/glycolysis and its potential value i developing new treatment for glioma. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.
基金：
Zhejiang Basic Public Welfare Research
Projects(Nature Science Foundation of
Zhejiang province), Grant/Award Number:
Q20H160004; Basic Research Program of
Yunnan Province (key project of Kunming
Medical Association) and Yunnan Medical
Leading Talents Project Fund,
Grant/Award Number:
202001AY070001‐160
第一作者机构：[1]Department of Orthopedics, Huzhou Cent Hospital, Affiliated Cent Hospital HuZhou University, Huzhou, China
共同第一作者：
通讯作者：
通讯机构：[3]Department of Neurosurgery, Huzhou Cent Hospital, Affiliated Cent Hospital HuZhou University, Huzhou, China[*1]Department of Neurosurgery, Huzhou Cent Hospital, Affiliated Cent Hospital HuZhou University, 1558 Sanhuan North Road, Huzhou 313000, China.
推荐引用方式(GB/T 7714)：
Qian Yafang,Ding Peng,Xu Jie,et al.CCL2 activates AKT signaling to promote glycolysis and chemoresistance in glioma cells.[J].CELL BIOLOGY INTERNATIONAL.2022,46(5):819-828.doi:10.1002/cbin.11778.
APA：
Qian Yafang,Ding Peng,Xu Jie,Nie Xiaohu&Lu Bin.(2022).CCL2 activates AKT signaling to promote glycolysis and chemoresistance in glioma cells..CELL BIOLOGY INTERNATIONAL,46,(5)
MLA：
Qian Yafang,et al."CCL2 activates AKT signaling to promote glycolysis and chemoresistance in glioma cells.".CELL BIOLOGY INTERNATIONAL 46..5(2022):819-828
